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Definition  
Diabetes mellitus (DM) or  diabetes is a group of a chronic, often debilitating 
and sometimes fatal, incurable, costly, and increasing but largely preventable 
non-communicable metabolic diseases that causes high blood sugar (glucose) 
levels when the body is unable to produce or effectively use insulin with 
unique multisystem complications of microvascular endpoints, including 
retinopathy, nephropathy, neuropathy, and macrovascular endpoints in forms 
of ischaemic heart disease, stroke and peripheral vascular disease). 
 
There are three main types of DM: 
• Type 1 (insulin-dependent DM or juvenile DM) results from the pancreas's 
failure to produce enough insulin,  
• Type 2 (non insulin-dependent DM or adult-onset DM) begins with insulin 
resistance, when body cells fail to respond to insulin properly,  
• Gestational occurs when pregnant women without a previous history of 
DM develop high blood-sugar levels. 
 
Epidemiology 1   
• DM is one of the most common endocrine 
disorders affecting almost 6% of the world's 
population.  
• The number of patients will reach 300 million 
in 2025 (International Diabetes Federation, 
2001).  
• More than 97% of these patients will have 
type II DM.   
http://www.ncbi.nlm.nih.gov/pubmed/17151290 http:// 
Epidemiology 2   
http:// http://www.ncbi.nlm.nih.gov/pubmed/17151290 
Risk Factors  
Type 1 DM 
• Family history   
• Environmental factors 
(exposure to a viral illness) 
• The presence of damaging 
immune system cells 
(autoantibodies) 
• Dietary factors (low vitamin D 
consumption, early exposure 
to cow's milk formula, and 
exposure to cereals before 4 
months of age) 
• Geography (Finland, Sweden, 
etc.). 
Type 2 DM 
• Family history 
• Race (Blacks, 
Hispanics, American 
Indians, Asian-
Americans) 
• Age (risk increases with 
age) 
• Gestational diabetes 
• Polycystic ovary 
syndrome (women) 
• High blood pressure  
• Abnormal cholesterol 
and triglyceride levels.  
http://www.mayoclinic.org/diseases-conditions/diabetes/basics/risk-factors/con-20033091 
Gestational DM 
• Family or personal 
history 
• Race (Black, 
Hispanic, American 
Indian or Asian are 
more likely to 
develop gestational 
diabetes) 
• Age (women older 
25 are at increased 
risk) 
• Weight (being 
overweight before 
pregnancy increases 
risk). 
Etiology  
Type 1 DM   
• Type 1 DM is characterized by loss of the insulin-producing beta 
cells of the islets of Langerhans in the pancreas, leading to insulin 
deficiency 
• The majority of type 1 DM is of the immune-mediated nature, in 
which a T-cell-mediated autoimmune attack leads to the loss of beta 
cells and thus insulin 
• Sensitivity and responsiveness to insulin are usually normal, 
especially in the early stages 
• Type 1 DM can affect children or adults, but was traditionally termed 
"juvenile diabetes" because a majority of these diabetes cases were 
in children 
• Type 1 DM can be accompanied by irregular and unpredictable high 
blood sugar levels, frequently with ketosis, and sometimes with 
serious low blood sugar levels 
• Type 1 DM is partly inherited, with multiple genes, including 
certain HLA genotypes, and can be triggered by one or more 
environmental factors, such as a viral infection or diet (gliadin (a 
protein present in gluten)). 
https://en.wikipedia.org/wiki/Diabetes_mellitus#Type_1 
Etiology  
Type 2 DM   
• Type 2 DM is characterized by insulin resistance, which 
may be combined with relatively reduced insulin 
secretion. 
• The defective responsiveness of body tissues to insulin is 
believed to involve the insulin receptor.  
• In the early stage of type 2, the predominant 
abnormality is reduced insulin sensitivity.   
• Type 2 DM is due primarily to lifestyle factors and 
genetics (obesity, lack of physical activity, poor diet, 
stress,  urbanization) 
• Dietary factors also influence the risk of developing 
type 2 DM (sugar-sweetened drinks, saturated fats, trans 
fatty acids, white rice).  
https://en.wikipedia.org/wiki/Diabetes_mellitus#Type_1 
Etiology  
Gestational DM   
• Gestational diabetes mellitus (GDM) resembles type 2 DM in 
several respects, involving a combination of relatively 
inadequate insulin secretion and responsiveness and occurs in 
2–10% of all pregnancies) 
• After pregnancy approximately 5–10% of women with 
gestational DM found to have most commonly type 2 DM 
• Gestational DM is fully treatable, but requires careful medical 
supervision throughout the pregnancy 
• Gestational DM can damage the health of the fetus or mother, 
and risks to the baby include macrosomia (high birth weight), 
congenital heart and central nervous 
system abnormalities, skeletal muscle malformations, 
respiratory distress syndrome, and red blood cell destruction.   
https://en.wikipedia.org/wiki/Diabetes_mellitus#Type_1 
Mechanisms 
Type 1 DM: 1 
• Type 1 DM is the culmination of autoimmune inflammatory 
lymphocytic infiltration with destruction of insulin-secreting 
beta cells of the islets of Langerhans in the pancreas  
• As beta-cell mass declines, insulin secretion decreases until 
the available insulin no longer is adequate to maintain normal 
blood glucose levels  
• After 80-90% of the beta cells are destroyed, hyperglycemia 
develops and diabetes may be diagnosed  
• Polymorphisms of the class II human leukocyte antigen (HLA) 
genes that encode DR and DQ are the major genetic 
determinants of type 1 DM.   
http://emedicine.medscape.com/article/117739-overview#a3 
Mechanisms 
Type 1 DM: 2 
http://d6igaq6njxgjh.cloudfront.net/content/physrev/91/1/79/F2.large.jpg 
Mechanisms 
Type 1 DM and Neuropathy: 1 
• Sensory and autonomic neuropathy in people with DM are 
caused by axonal degeneration and segmental demyelination 
• Many factors are involved, including the accumulation of 
sorbitol in peripheral sensory nerves from sustained 
hyperglycemia 
• Motor neuropathy and cranial mononeuropathy result from 
vascular disease in blood vessels supplying nerves. 
http://emedicine.medscape.com/article/117739-overview#a3 
Mechanisms 
Type 1 DM and Neuropathy: 2 
http://www.remap-ec.eu/images/diabetes-big-toe-joint-pain-washington-kent-30418.jpg 
Mechanisms 
Type 1 DM and Angiopathy: 1 
• Microvascular disease causes multiple pathologic 
complications in people with DM 
• Hyaline arteriosclerosis, a characteristic pattern of wall 
thickening of small arterioles and capillaries, is widespread 
and is responsible for ischemic changes in the kidney, retina, 
brain, and peripheral nerves 
• Atherosclerosis of the main renal arteries and their intrarenal 
branches causes chronic nephron ischemia 
• Vitamin D deficiency is an important independent predictor of 
development of coronary artery calcification in individuals 
with type 1 DM.  
http://emedicine.medscape.com/article/117739-overview#a3 
Mechanisms 
Type 1 DM and Angiopathy: 2 
https://www.ole.bris.ac.uk/bbcswebdav/institution/Faculty%20of%20Health%20Sciences/MB%20ChB%20Medicine 
Mechanisms 
Type 1 DM and Nephropathy: 1 
• In the kidneys, the characteristic wall thickening of small 
arterioles and capillaries leads to diabetic nephropathy, which 
is characterized by proteinuria, glomerular hyalinization 
(Kimmelstiel-Wilson), and chronic renal failure 
• Exacerbated expression of cytokines such as tumor growth 
factor beta 1 is part of the pathophysiology of 
glomerulosclerosis, which begins early in the course of 
diabetic nephropathy 
• Single-nucleotide polymorphisms affecting the factors 
involved in its pathogenesis appear to influence the risk for 
diabetic nephropathy in different people with type 1 DM.  
http://emedicine.medscape.com/article/117739-overview#a3 
Mechanisms 
Type 1 DM and Nephropathy: 2 
http://image.slidesharecdn.com/diabeticnephropathy-management-130816073518-phpapp02/95/diabetic-nephropathy-management-8-638.jpg%253Fcb%253D1376638790 
Mechanisms 
Type 1 DM and Nephropathy: 3 
• Histological 
comparison of a 
healthy glomerulus 
and a glomerulus in 
diabetic nephropathy  
• One can notice an 
augmentation of the 
mesangial matrix 
• The matrix appears in 
light pink and has a 
nodular structure, the 
capillary lumen is 
obstructed 
• This condition is called 
complete glomerular 
sclerosis.  
http://dccdn.de/pictures.doccheck.com/images/dd9/5b9/dd95b99fddc71cf75775eb17075da39f/52052/m_1407853118.jpg 
Mechanisms 
Type 1 DM: Double diabetes 
In areas where rates of 
type 2 DM and obesity 
are high, individuals 
with type 1 DM may 
share genetic and 
environmental factors 
that lead to their 
exhibiting type 2 DM 
features such as reduced 
insulin sensitivity 
(double diabetes).  
http://cdn.abclocal.go.com/images/wls/cms_exf_2007/_video_wn_images/8917654_1280x720.jpg http://emedicine.medscape.com/article/117739-overview#a3 
Mechanisms 
Type 2 DM 
• Type 2 DM is characterized by a combination of peripheral insulin 
resistance and inadequate insulin secretion by pancreatic beta cells 
• Insulin resistance, which has been attributed to elevated levels of 
free fatty acids and proinflammatory cytokines in plasma, leads to 
decreased glucose transport into muscle cells, elevated hepatic 
glucose production, and increased breakdown of fat 
• A role for excess glucagon cannot be underestimated; indeed, type 
2 diabetes is an islet paracrinopathy in which the reciprocal 
relationship between the glucagon-secreting alpha cell and the 
insulin-secreting beta cell is lost, leading to hyperglucagonemia and 
hence the consequent hyperglycemia   
• With prolonged diabetes, atrophy of the pancreas may occur.  
http://emedicine.medscape.com/article/117853-overview?pa=CgeHjeSgk%2FcDlbsbhmDMA9cE2X%2BmOE54EaA2Xw4hfL8ZpJ81sdgi18lmhYSYbGLT8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
Mechanisms 
Type 2 DM: Scheme of abnormal glucose metabolism 
http://emedicine.medscape.com/article/117853-overview?pa=CgeHjeSgk%2FcDlbsbhmDMA9cE2X%2BmOE54EaA2Xw4hfL8ZpJ81sdgi18lmhYSYbGLT8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
Mechanisms 
Type 2 DM and Beta-cell Dysfunction: 1 
• Beta-cell dysfunction is a major factor across the spectrum of 
prediabetes to DM 
• Beta-cell dysfunction develops early in the pathologic process 
and does not necessarily follow the stage of insulin resistance 
• Singular focus on insulin resistance as the "be all and end all" 
is gradually shifting, and hopefully better treatment options 
that address the beta-cell pathology will emerge for early 
therapy.  
http://emedicine.medscape.com/article/117853-overview?pa=CgeHjeSgk%2FcDlbsbhmDMA9cE2X%2BmOE54EaA2Xw4hfL8ZpJ81sdgi18lmhYSYbGLT8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
Mechanisms 
Type 2 DM and Beta-cell Dysfunction: 2 
http://www.intechopen.com/source/html/45317/media/image2.png 
Mechanisms 
Type 2 DM and Insulin Resistance: 1 
• In the progression from normal to abnormal glucose 
tolerance, postprandial blood glucose levels increase first 
• Eventually, fasting hyperglycemia develops as suppression of 
hepatic gluconeogenesis fails 
• During the induction of insulin resistance (such as occurs with 
a high-calorie diet, steroid administration, or physical 
inactivity), increased glucagon levels and increased glucose-
dependent insulinotropic polypeptide (GIP) levels accompany 
glucose intolerance 
• The postprandial glucagonlike peptide-1 (GLP-1) response is 
unaltered.  
http://emedicine.medscape.com/article/117853-overview?pa=CgeHjeSgk%2FcDlbsbhmDMA9cE2X%2BmOE54EaA2Xw4hfL8ZpJ81sdgi18lmhYSYbGLT8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
Mechanisms 
Type 2 DM and Insulin Resistance: 2 
• Insulin resistance means the signal 
insulin gives to a cell is weakened 
• This results in less glucose uptake 
by muscle and fat cells and a 
reduction in insulin mediated 
activities inside cells 
• Compounding this problem of 
resistance, there is additional 
defect in insulin production and 
secretion by the insulin producing 
beta cells in the pancreas. 
https://dtc.ucsf.edu/types-of-diabetes/type2/understanding-type-2-diabetes/what-is-type-2-diabetes/ 
Mechanisms 
Type 2 DM: Genomic factors 
• Genome-wide association studies of single-nucleotide 
polymorphisms (SNPs) have identified a number of genetic 
variants that are associated with beta-cell function and insulin 
resistance 
• Some of these SNPs appear to increase the risk for type 2 
diabetes 
• Over 40 independent loci demonstrating an association with 
an increased risk for type 2 diabetes have been shown.  
http://emedicine.medscape.com/article/117853-overview?pa=CgeHjeSgk%2FcDlbsbhmDMA9cE2X%2BmOE54EaA2Xw4hfL8ZpJ81sdgi18lmhYSYbGLT8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
Mechanisms 
Gestational DM: 1 
• If the maternal pancreatic insulin response is inadequate, 
maternal and, then, fetal hyperglycemia results, that are the 
most significant source of the accelerated growth exhibited by 
the fetus 
• Surging maternal and fetal glucose levels are accompanied by 
episodic fetal hyperinsulinemia 
• Fetal hyperinsulinemia promotes excess nutrient storage, 
resulting in macrosomia. The energy expenditure associated with 
the conversion of excess glucose into fat causes depletion in fetal 
oxygen levels that are accompanied by surges in adrenal 
catecholamines, which, in turn, cause hypertension, cardiac 
remodeling and hypertrophy, stimulation of erythropoietin, red 
cell hyperplasia, and increased hematocrit.   
http://emedicine.medscape.com/article/127547-overview#a4 
Mechanisms 
Gestational DM: 2 
http://usmle.biochemistryformedics.com/answer-case-study-gestational-diabetes-mellitus-and-neonatal-hypoglycemia-a-patient-who-had-gestational-diabetes-has-just-delivered/ 
Classification 
(American Diabetes Association) 
http://care.diabetesjournals.org/content/27/suppl_1/s5 
• Type 1 DM (β-cell destruction, usually leading to absolute 
insulin deficiency): immune-mediated, idiopathic 
• Type 2 DM (ranging from predominantly insulin resistance 
with relative insulin deficiency to predominantly an insulin 
secretory defect with insulin resistance) 
• Gestational DM (GDM) (diabetes diagnosed in the second or 
third trimester of pregnancy that is not clearly overt DM) 
• Other specific types of DM: genetic defects of the β-cell, 
genetic defects in insulin action, diseases of the exocrine 
pancreas, endocrinopathies, drug- or chemical-induced DM, 
infections, uncommon forms of immune-mediated DM, other 
genetic syndromes sometimes associated with DM, impaired 
glucose tolerance (IGT) and impaired fasting glucose (IFG). 
 
Classification 
(International Classification of Diseases (ICD)) 
http://apps.who.int/classifications/icd10/browse/2016/en#/E10-E14 / 
IV Endocrine, nutritional and metabolic diseases  
 (E10-E14) Diabetes mellitus 
 E10  Type 1 diabetes mellitus 
 E11  Type 2 diabetes mellitus 
 E12  Malnutrition-related diabetes mellitus 
 E13  Other specified diabetes mellitus 
 E14  Unspecified diabetes mellitus 
XV Pregnancy, childbirth and the puerperium   
 O20-O29 Other maternal disorders predominantly 
related to pregnancy   
 O24 Diabetes mellitus in pregnancy  
Clinical Investigation  
(Signs and Symptoms: 1) 
• The classic symptoms of untreated DM are weight 
loss, polyuria (increased urination), polydipsia (increased 
thirst), and polyphagia(increased hunger) that may develop 
rapidly (weeks or months) in type 1 DM, while they usually 
develop much more slowly and may be subtle or absent in 
type 2 DM 
• Several other signs and symptoms are not specific to DM and 
include blurry vision, headache, fatigue, slow healing of cuts, 
and itchy skin 
• Prolonged high blood glucose can cause glucose absorption 
in the lens of the eye, which leads to changes in its shape, 
resulting in vision changes 
• A number of skin rashes are collectively known as diabetic 
dermatomes. 
https://en.wikipedia.org/wiki/Diabetes_mellitus#Signs_and_symptoms 
Clinical Investigation  
(Signs and Symptoms: 2) 
https://thumbs.dreamstime.com/z/diabetes-mellitus-diabetic-signs-symptoms-clipart-illustrations-showing-disease-such-as-weight-loss-extreme-tiredness-61592413.jpg 
Clinical Investigation  
(Signs and Symptoms: 3) 
http://www.soccerpluseducation.org/images/treatment-for-type-i-and-type-ii-diabetes-80009.jpg 
Clinical Investigation  
(Diabetic emergencies: 1) 
• Low blood sugar is common in patients with DM, but most cases are 
mild and are not considered medical emergencies 
• Effects can range from feelings of unease, sweating, trembling, and 
increased appetite in mild cases to more serious issues such 
as confusion, aggressiveness, seizures, unconsciousness, and (rarely) 
permanent brain damage or death in severe cases 
• Moderate hypoglycemia may easily be mistaken for drunkenness 
• People (usually with type 1 DM) may also experience episodes 
of diabetic ketoacidosis, characterized by nausea, vomiting 
and abdominal pain, the smell of acetone on the breath, deep 
(Kussmaul) breathing, and a decreased level of consciousness 
• A rare possibility is hyperosmolar nonketotic state, which is more 
common in type 2 DM and is mainly the result of dehydration 
https://en.wikipedia.org/wiki/Diabetes_mellitus#Signs_and_symptoms 
Clinical Investigation  
(Diabetic emergencies: 2) 
http://www.healthline.com/hlcmsresource/images/diabetesmine/wp-content/uploads/2013/11/Low-Blood-Sugar-Symptoms.jpg 
Clinical Investigation  
(Diabetic emergencies: 3) 
Diabetic ketoacidosis (DKA) 
https://dtc.ucsf.edu/living-with-diabetes/complications/diabetic-ketoacidosis/ 
Clinical Investigation  
(Diabetic emergencies: 4) 
Diagnostic triad of diabetic ketoacidosis (DKA) 
http://image.slidesharecdn.com/diabetesketoacidosis-140217063120-phpapp01/95/diabetes-ketoacidosis-4-638.jpg?cb=1392618740 
Clinical Investigation  
(Diabetic emergencies: 5) 
Differences in diabetic ketoacidosis (DKA) and hyperosmolar nonketotic state (HONK) 
http://www.derangedphysiology.com/main/required-reading/endocrinology-metabolism-and-nutrition/Chapter%202.1.2/hyperosmolar-non-ketotic-hypergycaemic-coma-honk 
Clinical Investigation  
(Complications: 1) 
• The major long-term complications relate to damage to blood 
vessels with the risk of "macrovascular" diseases development 
(coronary artery disease, stroke, peripheral vascular disease) 
• The primary complications of diabetes due to damage in small blood 
vessels include damage to the eyes, kidneys, and nerves (diabetic 
retinopathy that result in gradual vision loss and blindness, diabetic 
nephropathy that leads to chronic kidney disease,  diabetic 
neuropathy, diabetes-related foot problems (diabetic foot ulcers, 
occasionally requiring amputation), proximal diabetic 
neuropathy that causes painful muscle wasting and weakness, 
cognitive deficit . 
https://en.wikipedia.org/wiki/Diabetes_mellitus#Signs_and_symptoms 
Clinical Investigation  
(Complications: 2) 
http://www.imhealth.com/wp-content/uploads/2015/02/complications.jpg 
Clinical Investigation  
(Complications: Peripheral Neuropathy) 
• Numbness or reduced ability to feel pain or temperature 
changes 
• A tingling or burning sensation 
• Sharp pains or cramps 
• Increased sensitivity to touch — for some people, even the 
weight of a bed sheet can be agonizing 
• Muscle weakness 
• Loss of reflexes, especially in the ankle 
• Loss of balance and coordination 
• Serious foot problems, such as ulcers, infections, deformities, 
and bone and joint pain 
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
(Complications: Autonomic Neuropathy) 
• A lack of awareness that blood sugar levels are low (hypoglycemia unawareness) 
• Bladder problems (urinary tract infections, urinary retention or incontinence) 
• Constipation and/or uncontrolled diarrhea 
• Slow stomach emptying (gastroparesis), leading to nausea, vomiting, bloating 
and loss of appetite 
• Difficulty swallowing 
• Erectile dysfunction in men 
• Vaginal dryness and other sexual difficulties in women 
• Increased or decreased sweating 
• Inability of patient’s body to adjust blood pressure and heart rate, leading to 
sharp drops in blood pressure after sitting or standing that may cause him to 
faint or feel lightheaded 
• Problems regulating body temperature 
• Changes in the way eyes adjust from light to dark 
• Increased heart rate at rest 
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
(Complications: Radiculoplexus Neuropathy) 
• Radiculoplexus neuropathy (diabetic amyotrophy, femoral neuropathy, 
proximal neuropathy) affects nerves in the thighs, hips, buttocks or 
legs more common in older adults with type 2 DM  
• Symptoms are usually on one side of the body, though in some cases 
symptoms may spread to the other side 
• Most people improve at least partially over time, though symptoms 
may worsen before they get better 
• This condition is often marked by: 
• Sudden, severe pain in hip and thigh or buttock 
• Eventual weak and atrophied thigh muscles 
• Difficulty rising from a sitting position 
• Abdominal swelling, if the abdomen is affected 
• Weight loss 
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
(Complications: Mononeuropathy) 
• Mononeuropathy (focal neuropathy) involves damage to a specific 
nerve and it's most common in older adults 
• Mononeuropathy can cause severe pain, it usually doesn't cause any 
long-term problems 
• Signs and symptoms depend on which nerve is involved and may 
include: difficulty focusing eyes, double vision or aching behind one 
eye; paralysis on one side of the face (Bell's palsy); pain in a shin or 
foot; pain in a lower back or pelvis;  pain in the front of a thigh, pain in 
the chest or abdomen 
• Sometimes mononeuropathy occurs when a nerve is compressed, e.g.  
carpal tunnel syndrome  (numbness or tingling in fingers or hand, 
especially in thumb, index finger, middle finger and ring finger, etc.).  
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
(Complications: Diabetic Foot Ulcers) 
• Diabetic foot ulcers  occur in 15% of people 
with DM and precedes 84% of all diabetes-
related lower-leg amputations  
• Risk factors are diabetic 
neuropathy, peripheral vascular disease, 
cigarette smoking, poor glycemic control, 
previous foot ulcerations or amputations, 
diabetic nephropathy, and ischemia of small 
and large blood vessels  
• Diabetic foot lesions are responsible for 
more hospitalizations than any other 
complication of diabetes 
https://www.cs.montana.edu/webworks/projects/stevesbook/artifacts/images/chapter_003/Section002/DiabeticFootUlcer350w.jpg http://emedicine.medscape.com/article/460282-overview 
Diagnosis  
World Health Organization (WHO) Criteria 
Methods and criteria for diagnosing diabetes 
• Diabetes symptoms (e.g. polyuria, polydipsia and unexplained 
weight loss for Type 1) plus: 
– a random venous plasma glucose concentration ≥ 11.1 mmol/l or 
– a fasting plasma glucose concentration ≥ 7.0 mmol/l (whole 
blood ≥ 6.1 mmol/l) or 
– two hour plasma glucose concentration ≥ 11.1 mmol/l two hours 
after 75g anhydrous glucose in an oral glucose tolerance test 
(OGTT). 
• With no symptoms diagnosis should not be based on a single 
glucose determination but requires confirmatory plasma venous 
determination.   
https://www.diabetes.org.uk/About_us/What-we-say/Diagnosis-ongoing-management-monitoring/New_diagnostic_criteria_for_diabetes/ 
Diagnosis  
World Health Organization (WHO) Criteria 
Gestational diabetes 
The criteria for diagnosing gestational diabetes is different.  
Gestational diabetes should be diagnosed if the woman has either: 
• a fasting plasma glucose level of 5.6mmol/l or above or 
• a 2-hour plasma glucose level of 7.8mmol/l or above. 
https://www.diabetes.org.uk/About_us/What-we-say/Diagnosis-ongoing-management-monitoring/New_diagnostic_criteria_for_diabetes/ 
Diagnosis  
World Health Organization (WHO) Criteria 
Glycated Hemoglobin A1c (HbA1c) testing to diagnose diabetes 
• An HbA1c of 48mmol/mol (6.5%) is recommended as the cut off 
point for diagnosing diabetes  
• Finger-prick HbA1c should not be used unless the methodology and 
the healthcare staff and facility using it can demonstrate within the 
national quality assurance scheme that they match the quality 
assurance results found in laboratories  
• In patients without symptoms of diabetes the laboratory venous 
HbA1c should be repeated, and if the second sample is 
<48mmol/mol (6.5%) the person should be treated as at high risk of 
diabetes and the test should be repeated in 6 months or sooner if 
symptoms develop. 
https://www.diabetes.org.uk/About_us/What-we-say/Diagnosis-ongoing-management-monitoring/New_diagnostic_criteria_for_diabetes/ 
Diagnosis  
Glycated hemoglobin (Hb A1C) test 
• Glycated hemoglobin (Hb A1C) test indicates average blood 
sugar level for the past two to three months 
• Glycated hemoglobin (Hb A1C) test measures the percentage 
of blood sugar attached to hemoglobin, the oxygen-carrying 
protein in red blood cells 
• The higher blood sugar levels, the more hemoglobin patient 
will have with sugar attached 
• An Hb A1C level of 6.5 percent or higher on two separate tests 
indicates that patient have diabetes 
• An Hb A1C between 5.7 and 6.4 percent indicates prediabetes 
• Below 5.7 is considered normal. 
http://www.mayoclinic.org/diseases-conditions/diabetes/basics/tests-diagnosis/con-20033091 
Diagnosis  
World Health Organization (WHO) Criteria 
https://en.wikipedia.org/wiki/Diabetes_mellitus#Signs_and_symptoms 
Condition 
2 hour glucose Fasting glucose Hb A1C 
mmol/l(mg/dl) mmol/l(mg/dl) mmol/mol DCCT % 
Normal <7.8 (<140) <6.1 (<110) <42 <6.0 
Impaired fasting 
glycaemia 
<7.8 (<140) 
≥6.1(≥110) & 
<7.0(<126) 
42-46 6.0–6.4 
Impaired 
glucose 
tolerance 
≥7.8 (≥140) <7.0 (<126) 42-46 6.0–6.4 
Diabetes 
mellitus 
≥11.1 (≥200) ≥7.0 (≥126) ≥48 ≥6.5 
Management  
(Organization of DM Care) 
• All people with DM should be receiving continuing preventative 
care through education and medical interventions 
• All people with DM need annual surveillance to detect early on 
the development of late tissue damage, and where this is 
detected access to protocols and resources for its management  
• All people with DM should have continuing access to DM team, 
for help in management and social difficulties arising from DM 
• All people with DM have a role in the development and 
organization of the service of which they are a part  
• All DM management teams should have an active policy of 
quality improvement   
• Appropriate special care should be offered to those with special 
needs, including pregnant women. 
https://www.staff.ncl.ac.uk/philip.home/iddmch1.htm#Delivery 
Management  
(Diet and Activity) 
• All patients on insulin should have a comprehensive diet plan, 
created with the help of a professional dietitian, that includes 
the following: 
• A daily caloric intake prescription 
• Recommendations for amounts of dietary carbohydrate, fat, 
and protein 
• Instructions on how to divide calories between meals and 
snacks 
• Exercise is also an important aspect of diabetes management. 
Patients should be encouraged to exercise regularly. 
http://emedicine.medscape.com/article/117739-overview#showall 
Management  
(Self-Monitoring in Glycemic Control) 
• Benefits of tight glycemic control include not only continued 
reductions in the rates of DM complications but also in overall 
mortality 
• Optimal DM control requires frequent self-monitoring of blood 
glucose levels, which allows rational adjustments in 
hypoglycemic medications 
•  All patients should learn how to self-monitor and record their 
blood glucose levels with home analyzers and adjust their 
hypoglycemic medications doses accordingly 
• Real-time continuous monitoring of glucose—using continuous 
glucose monitors (CGMs)—can help patients improve glycemic 
control.  
http://emedicine.medscape.com/article/117739-overview#showall 
Management  
(Continuous Glucose Monitors (CGMs)) 
Continuous glucose 
monitors (CGMs)contain 
subcutaneous sensors 
that measure interstitial 
glucose levels every 1-5 
minutes, providing alarms 
when glucose levels are 
too high or too low or are 
rapidly rising or falling. 
 
https://www.medtronicdiabetes.ca/sites/canada/www.medtronicdiabetes.ca/files/styles/245px_list_image/public/veoml-on-body_1.jpg?itok=CIC_4ZHY 
http://blog.amal.net/wp-content/uploads/2010/02/glucose_monitoring.jpg http://emedicine.medscape.com/article/117739-overview#showall 
Implantable 
Management  
(Glucose Meters) 
http://diabetespharmacist.wp.lexblogs.com/wp-content/uploads/sites/346/2013/09/Blood-glucose-monitors.jpg 
https://upload.wikimedia.org/wikipedia/commons/6/62/Blausen_0301_Diabetes_GlucoseMonitoring.png 
Implantable 
Management 
(Objectives of DM Management) 
https://www.staff.ncl.ac.uk/philip.home/iddmch1.htm#Delivery 
Management  
(Insulin: Therapy) 
• Patients with type 1 DM require lifelong insulin therapy 
• Most require 2 or more injections of insulin daily, with 
doses adjusted on the basis of self-monitoring of blood 
glucose levels 
• Insulin replacement is accomplished by giving a basal 
insulin and a preprandial (premeal) insulin 
• The basal insulin is either long-acting (glargine or detemir) 
or intermediate-acting (NPH) 
• The preprandial insulin is either rapid-acting (lispro, 
aspart, insulin inhaled, or glulisine) or short-acting 
(regular). 
http://emedicine.medscape.com/article/117739-overview#showall 
Management  
(Insulin: Types) 
The commonly used types of insulin in DM patients  are:  
i) fast-acting which begin to work within 5 to 15 minutes and are active for 3 to 4 
hours  
ii) short-acting which begins working within 30 minutes and is active about 5 to 8 
hours  
iii) intermediate-acting, includes NPH insulin which begins working in 1 to 3 hours 
and is active 16 to 24 hours; long acting, which begins working within 1 to 2 
hours and continue to be active, without major peaks or dips, for about 24 
hours, although this varies in many individuals 
iv) ultra-long acting,  which begins working within 30–90 minutes, and continues 
to be active for greater than 24 hours 
v) combination insulin products, which include a combinations of either fast-
acting or short-acting insulin with a longer acting insulin and begin to work 
with the shorter acting insulin (5–15 minutes for fast-acting, and 30 minutes 
for short acting), and remain active for 16 to 24 hours.   
 
https://en.wikipedia.org/wiki/Insulin_(medication) 
Management  
(Insulin: Methods of Administration) 
• Insulin is usually taken as subcutaneous injections by single-use 
syringes with needles, an insulin pump, by repeated-use insulin 
pens with needles, or by use an injection port in conjunction 
with syringes  
• Administration schedules often attempt to mimic the 
physiologic secretion of insulin by the pancreas  
• Insulin pumps are a reasonable solution for some, and 
advantages are better control over background or 'basal' insulin 
dosage, bolus doses calculated to fractions of a unit, and 
calculators in the pump that may help with determining 'bolus' 
infusion dosages 
• Insulin pumps may be like 'electrical injectors' attached to a 
temporarily implanted catheter or cannula.  
https://en.wikipedia.org/wiki/Insulin_(medication) 
Management  
(Insulin: Insulin Pump) 
http://images.dailytech.com/nimage/21235_large_Insulin-Pump.jpg http://blogs.discovermagazine.com/d-brief/files/2013/06/insulin-pump.jpg 
Management  
(Insulin: Dosage and Timing) 
• One international unit of insulin (1 IU) is defined as 
the "biological equivalent" of 34.7 μg pure crystalline 
insulin 
• The unit of measurement used in insulin therapy is 
not part of the International System of 
Units (abbreviated SI) which is the modern form of 
the metric system 
• Instead the pharmacological international unit (IU) is 
defined by the WHO Expert Committee on Biological 
Standardization. 
https://en.wikipedia.org/wiki/Insulin_(medication) 
Management  
(Insulin: Multiple Daily Injections) 
http://dtc.ucsf.edu/images/graphs/graph_intense_type1.gif 
Management  
(Insulin: Sample regimen using insulin NPH and regular insulin) 
https://en.wikipedia.org/wiki/Insulin_(medication) 
 
before breakfast 
before lunch before dinner at bedtime 
NPH dose 12 units 6 units 
regular insulin dose if 
fingerstick 
glucose is (mg/dl) 
[mmol/L]: 
70-100       [3.9-5.5] 4 units 4 units 
101-150     [5.6-8.3] 5 units 5 units 
151-200     [8.4-11.1] 6 units 6 units 
201-250     [11.2-13.9] 7 units 7 units 
251-300     [14.0-16.7] 8 units 1 unit 8 units 1 unit 
>300         [>16.7] 9 units 2 units 9 units 2 units 
Management  
(Insulin Administration) 
http://www.chkd.org/Images/W2G%20Health%20Library/diabetes6.jpg 
Management  
( Treatment of Type 2 DM) 
• Individualized glycemic targets and glucose-lowering therapies 
• Diet, exercise, and education as the foundation of the 
treatment program 
• Use of metformin as the optimal first-line drug unless 
contraindicated 
• After metformin, the use of 1 or 2 additional oral or injectable 
agents, with a goal of minimizing adverse effects if possible 
• Ultimately, insulin therapy alone or with other agents if needed 
to maintain blood glucose control 
• Where possible, all treatment decisions should involve the 
patient, with a focus on patient preferences, needs, and values 
• A major focus on comprehensive cardiovascular risk reduction 
http://emedicine.medscape.com/article/117853-overview?pa=CgeHjeSgk%2FcDlbsbhmDMA9cE2X%2BmOE54EaA2Xw4hfL8ZpJ81sdgi18lmhYSYbGLT8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Management  
(Oral Antihyperglycemic Drugs: Biguanides) 
• Biguanides decrease hepatic glucose production, decrease 
gastrointestinal glucose absorption, and increase target cell 
insulin sensitivity 
• Example: Metformin 
• Contraindications: Metabolic acidosis with or without coma, 
abnormal creatinine clearance from any cause 
including diabetic ketoacidosis, shock, acute myocardial 
infarction, septicemia, renal disease (serum creatinine level 
≥1.5 mg/dL in males or ≥1.4 mg/dL in females), lactation, 
radiologic contrast study within 48 hours 
http://emedicine.medscape.com/article/2172160-overview 
Management  
(Oral Antihyperglycemic Drugs: Sulfonylureas) 
• Sulfonylureas increase beta-cell insulin secretion, decrease 
hepatic glucose output, and increase insulin receptor sensitivity 
at peripheral target tissues 
• Examples: Glyburide, glipizide, glimepiride, 
tolazamide, tolbutamide 
• Contraindications: Sulfa allergy, type 1 DM, diabetic 
ketoacidosis, concomitant use with bosentan 
http://emedicine.medscape.com/article/2172160-overview 
Management  
(Oral Antihyperglycemic Drugs: Thiazolidinediones) 
• Thiazolidinediones increase insulin receptor sensitivity and 
influence the production of gene products involved in lipid and 
glucose metabolism; their mechanism of action depends on the 
presence of insulin for activity 
• Examples: Pioglitazone, rosiglitazone 
• Contraindications: Hypersensitivity to product or components, 
established NYHA class III/IV heart failure 
http://emedicine.medscape.com/article/2172160-overview 
Management  
(Oral Antihyperglycemic Drugs: Alpha-Glucosidase Inhibitors) 
• Inhibit the upper gastrointestinal enzymes that convert dietary 
starch and other complex carbohydrates into simple sugars, 
which can be absorbed 
• Examples: Acarbose (Precose) & Miglitol (Glycet) 
• Contraindications: Diabetic ketoacidosis; cirrhosis; 
inflammatory bowel disease, colonic ulceration, partial 
intestinal obstruction, 
http://emedicine.medscape.com/article/2172160-overview 
Management  
(Peptide analogs) 
• Injectable Incretin mimetics as insulin secretagogues:  glucagon-
like peptide-1 (GLP-1) analog  and gastric inhibitory peptide 
(glucose-dependent insulinotropic peptide, GIP) analog  
• Injectable Amylin analogues that slow gastric emptying and 
suppress glucagon have all the incretins actions except 
stimulation of insulin secretion 
• Glycosurics (SGLT-2 inhibitors) block the re-uptake of glucose in 
the renal tubules, promoting loss of glucose in the urine. 
 
 
 
https://en.wikipedia.org/wiki/Anti-diabetic_medication 
Management  
( Treatment of Gestational DM) 
• Diet: avoid single large meals and foods with a large percentage 
of simple carbohydrates 
• Insulin: the goal of insulin therapy during pregnancy is to 
achieve glucose profiles similar to those of nondiabetic 
pregnant women 
• Glyburide and metformin: trials have shown these 2 drugs to be 
effective, and no evidence of harm to the fetus has been found 
• Management of the neonate: the employment of frequent 
blood glucose checks and early oral feeding (ideally from the 
breast) when possible, with infusion of intravenous glucose if 
oral measures prove insufficient. 
http://emedicine.medscape.com/article/117853-overview?pa=CgeHjeSgk%2FcDlbsbhmDMA9cE2X%2BmOE54EaA2Xw4hfL8ZpJ81sdgi18lmhYSYbGLT8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Management  
(Surgery) 
• A pancreas transplant is occasionally considered for people 
with type 1 DM who have severe complications of their 
disease, including end stage kidney disease requiring kidney 
transplantation  
• Weight loss surgery in those with obesity and type 2 DM is 
often an effective measure 
• Many are able to maintain normal blood sugar levels with 
little or no medications following surgery and long-term 
mortality is decreased. 
https://en.wikipedia.org/wiki/Diabetes_mellitus#Lifestyle 
Prognosis  
• The general statistical prognosis is that 15% of sufferers of 
type 1 DM will die before the age of 40,  sensible blood sugar 
control and a healthy diet can lead to a long life for  sufferers  
• Contracting type 2 DM in  40’s means five to 10 years off  
average life expectancy; however, as with the above, this is a 
vast improvement on recent years 
• As Heart Disease is the leading cause of death in Type 2 DM 
sufferers, keeping to a regime that minimises the risk is very 
much recommended. 
http://www.medical1stop.com/diabetes-symptoms-causes-treatment-and-prognosis/ 
Prophylaxis  
• There is no known preventive measure for type 1 DM 
• Type 2 DM can often be prevented or delayed by maintaining 
a normal body weight, engaging in physical exercise, and 
consuming a healthful diet 
• Higher levels of physical activity reduce the risk of diabetes by 
28% 
• Dietary changes known to be effective in helping to prevent 
diabetes include maintaining a diet rich in whole grains and 
fiber, and choosing good fats, such as the polyunsaturated 
fats found in nuts, vegetable oils, and fish 
• The relationship between type 2 DM and the main modifiable 
risk factors (excess weight, unhealthy diet, physical inactivity 
and tobacco use) is similar in all regions of the world.   
https://en.wikipedia.org/wiki/Diabetes_mellitus#Prevention 
Abbreviations  
CGMs  - continuous glucose monitors 
DKA    - diabetic ketoacidosis 
DM     - diabetes mellitus 
GDM  - Gestational diabetes mellitus 
GIP     - glucose-dependent 
insulinotropic polypeptide  
GLP-1 - the postprandial glucagonlike 
peptide-1 
HbA1c - Glycated Hemoglobin A1c 
HLA    - human leukocyte antigen 
HONK - hyperosmolar nonketotic 
state 
IGT      - impaired glucose tolerance 
IFG      - impaired fasting glucose 
IU         - international unit of insulin 
NYHA  - New York Heart Association 
OGTT  - oral glucose tolerance test 
SGLT-2 - Sodium-glucose co-
transporter 2  
SNPs   - single-nucleotide 
polymorphisms 
WHO  - World Health Organization 
 
Diagnostic and treatment guidelines 
• IDF Clinical Practice Guidelines 
• Type 2 diabetes in adults: management 
• Diabetes in pregnancy: management from 
preconception to the postnatal period 
• Guidelines on diabetes, pre-diabetes, and 
cardiovascular diseases 
• Managing older people with type 2 diabetes: 
global guidelines(external link) 
 
 
